Mounjaro vs Ozempic: what is the difference?

Mounjaro vs Ozempic at a glance

Both are Schedule 4 medicines in South Africa: each requires a doctor's assessment and authorisation, and both are dispensed by licensed pharmacies only.

How do Mounjaro and Ozempic work differently?

Ozempic's semaglutide activates one gut-hormone receptor, GLP-1, which slows stomach emptying, reduces appetite and improves insulin response after meals. Mounjaro's tirzepatide activates that same receptor plus a second one, GIP, which appears to improve how the body handles fat and to amplify the GLP-1 effects. That extra receptor is the core difference between the two medicines.

The dual action is the leading explanation for the larger average weight loss seen in tirzepatide trials. It is a difference in biology, not a different kind of treatment: both remain once-weekly injections that work through appetite and blood-sugar regulation.

In daily life the two feel similar: reduced hunger, earlier fullness, quieter food noise. Both slow digestion, which is also why their side effects overlap so closely. The difference shows up in the trial averages rather than in how the injection week feels.

Which is better for weight loss, Mounjaro or Ozempic?

The direct evidence comes from SURMOUNT-5, a 72-week head-to-head trial of 751 adults with obesity, published in the New England Journal of Medicine in 2025. Tirzepatide at the highest tolerated dose produced 20.2% average weight loss against 13.7% for semaglutide 2.4 mg. Individual results vary.

One caveat matters: the semaglutide arm used the 2.4 mg weight-management dose, which is Wegovy's dose, higher than the doses Ozempic is registered for. There is no head-to-head at Ozempic's diabetes doses, so "Mounjaro beats Ozempic by 6.5 percentage points" overstates what the trial tested.

The single-medicine trials line up with the head-to-head. In STEP 1, semaglutide 2.4 mg averaged 14.9% weight loss over 68 weeks against 2.4% for placebo. In SURMOUNT-1, tirzepatide averaged 15% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks. Individual results vary, and in every trial participants also followed a reduced-calorie diet and activity plan.

Averages also hide the spread. In SURMOUNT-5, more tirzepatide participants reached the deeper weight-loss thresholds, yet both groups contained strong responders and modest responders. Whichever molecule someone starts on, their own response over the first months carries more weight than any trial average. Individual results vary.

For the molecule-level comparison across all brands and doses, see semaglutide vs tirzepatide.

What is each registered for in South Africa?

Ozempic is registered with SAHPRA for type 2 diabetes only. Mounjaro is registered for both type 2 diabetes and chronic weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition. The semaglutide product registered for weight management is Wegovy, at the higher 2.4 mg dose.

Mounjaro launched locally in December 2024 for type 2 diabetes, and in October 2025 SAHPRA approved the weight management indication, alongside a reduced-calorie diet and increased activity, for adults meeting the thresholds above.

Doctors sometimes encounter patients assuming Ozempic is the weight-loss product; formally, it is not. Registration shapes what a doctor can build a weight management plan around, which is why the two are not interchangeable on paper even where they overlap in practice.

How do the dose schedules compare?

Both start low and climb slowly, with four weeks as the minimum at each step. Ozempic starts at 0.25 mg weekly for four weeks, moves to 0.5 mg, and can rise to 1 mg locally. Mounjaro starts at 2.5 mg weekly and climbs in 2.5 mg steps to a maximum of 15 mg.

The milligram numbers are not comparable across the two: they are different molecules with different potencies, so 5 mg of tirzepatide is not "five times" 1 mg of semaglutide. What is comparable is the shape of the schedule: a non-treatment starting dose, stepped increases, and a maintenance dose your doctor sets and adjusts based on response and tolerability.

Both come as multi-dose pens holding four weekly doses, injected under the skin of the stomach, thigh or upper arm. The Mounjaro schedule, step by step, is in our Mounjaro dosage guide.

What are the Mounjaro and Ozempic pens like to use?

Both are multi-dose pens holding four weekly doses, injected under the skin with a screw-on pen needle. The Mounjaro KwikPen dials to one fixed dose per strength, while the Ozempic pen uses a dose counter you turn until it shows the dose your doctor set. Neither asks you to measure anything by hand.

The Mounjaro KwikPen holds four doses of a single strength, and the routine repeats each week: fresh needle on, prime, dial the fixed dose, inject, count slowly to five. After the fourth weekly injection the pen is finished and is discarded.

Ozempic comes in two pen sizes locally: a smaller pen that delivers 0.25 mg or 0.5 mg, and a larger pen that delivers 1 mg only. Each new pen needs a flow check before first use, and the dose counter, not the clicking of the dial, confirms the dose. Why click counting misleads is explained in Ozempic pen clicks.

Both pens live in the fridge at 2 to 8 degrees Celsius until first use, and each leaflet sets how long an in-use pen may stay out of the fridge. Ask the pharmacist to demonstrate whichever pen you collect the first time, use a sharps container for needles, and never share a pen, even with the needle changed.

Do Mounjaro and Ozempic have the same side effects?

Largely, yes. Both share the class side effects: nausea, diarrhoea, constipation, vomiting and indigestion, concentrated around dose increases and usually settling as the body adjusts. In SURMOUNT-5, gastrointestinal events were the most common side effects in both groups, at similar rates.

The exclusions overlap too. Neither should be used in pregnancy or while breastfeeding, or by people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and a history of pancreatitis needs careful discussion with a doctor first. Severe, persistent stomach pain on either medicine can signal pancreatitis: seek medical care immediately.

Individual tolerance differs, and some people who battle on one molecule do better on the other. That is a clinical judgement for your doctor, not a self-experiment.

Day-to-day management is identical for both: smaller meals, slower eating and steady hydration around dose increases, with a doctor review if symptoms drag on past a couple of weeks instead of settling.

Mounjaro vs Ozempic price in South Africa

At published 2026 prices, Ozempic pens range from roughly R1,400 to R3,100 per pen depending on strength, and Mounjaro KwikPens from about roughly R3,600 to R8,200. Each pen of either medicine holds four weekly doses, so those figures approximate a month. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

Ozempic publishes lower numbers, but the comparison is not clean: its registered doses and indication differ, and a weight management plan built on semaglutide at the registered weight-loss dose points to Wegovy, which is priced differently again.

Medical aid rarely changes the picture, since schemes generally do not fund weight management medicine, though some fund these medicines for type 2 diabetes under chronic benefits. Budgeting should also include consultations and follow-up reviews, which are billed separately from the medicine itself.

Why is the Mounjaro vs Ozempic price gap not fixed?

Because both prices are regulated and both manufacturers are competing. South Africa sets one national Single Exit Price for every medicine, pharmacies add only a regulated dispensing fee, and prices adjust within an annual cap. On top of that, competition in this class has already pushed published semaglutide prices down.

The Single Exit Price system means the same pen costs the same at Dischem, Clicks or an independent pharmacy, apart from small differences in the dispensing fee. Discounting is prohibited, so an online offer far below the going rate is a warning sign, not a bargain.

Dose moves the number more than the pharmacy does. Both schedules climb over the first months, each strength has its own pen price, and your monthly spend follows your dose. Budget for the strength you expect to hold rather than the starting pen.

Competition is reshaping the semaglutide side. Semaglutide's South African patent expired in March 2026, Novo Nordisk has cut Wegovy's local price since launch, and MedicalBrief reported in July 2026 that SAHPRA had approved the country's first generic semaglutide, an Ozempic equivalent, with more applications in review. Tirzepatide has no generic and its patents run for years, so any published comparison ages quickly. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

Which is easier to find in South Africa?

Both are stocked by Dischem, Clicks and independent community pharmacies, and individual strengths of each go out of stock at branch level. Ozempic supply has tightened globally several times since 2023 and South Africa felt it. Mounjaro launched locally in December 2024, and pharmacy supply has since settled on the KwikPen.

A stock gap is never a reason to improvise. Do not stretch doses, split pens or bridge a shortage through an informal seller: unregistered and compounded copies of both molecules circulate online, SAHPRA has warned the public about them, and their contents are not verified. A pharmacy can usually order stock within days, and your doctor can adjust the plan if a strength stays scarce.

Registration history, stock patterns and how dispensing works are covered in Mounjaro in South Africa and Ozempic in South Africa.

Can you switch between Ozempic and Mounjaro?

Yes, under a doctor's supervision, in either direction. The doses do not convert directly because the molecules differ in potency, so the doctor chooses a starting dose of the new medicine, times the first injection against the last dose of the old one, and monitors the first weeks of the change.

Doctors consider a switch for concrete reasons: side effects that do not settle despite slow dose increases, a plateau at the highest tolerated dose, a strength that stays out of stock, or cost. The decision weighs your history and response, not only the trial averages.

Do not run the two together or swap on your own. They act on overlapping receptors, timing and starting dose both need managing, and the common digestive side effects can resurface around any change while the body adjusts to the new molecule.

How do Saxenda and Wegovy fit into the comparison?

Mounjaro and Ozempic are two of four injectable options in this class in South Africa. Saxenda is a daily liraglutide injection registered for weight management, and Wegovy is weekly semaglutide at the higher 2.4 mg dose, also registered for weight management. A doctor chooses across all four, not these two alone.

The Wegovy point matters for anyone comparing on trial figures. Semaglutide's weight-management evidence, including the 2.4 mg arm in the head-to-head trial above, belongs to Wegovy's dose, so comparing Mounjaro with Ozempic alone understates what semaglutide can do for weight management.

The three-way comparison, with trial figures and South African registration status for each, is in Saxenda vs Ozempic vs Mounjaro.

Which one is right for you?

That is a clinical decision, not a shopping decision. A doctor weighs your health history, other conditions, side-effect risk, budget and goals against each medicine's registration, then confirms a treatment plan where medicine is clinically appropriate. For weight management specifically, Mounjaro holds the local registration, while semaglutide's weight registration belongs to Wegovy.

Practical factors count too. What your pharmacy can reliably stock month after month matters more than a few percentage points of trial average, because the medicine that works is the one you can actually stay on.

Trial averages favour tirzepatide, but averages are not individuals. Plenty of people reach their goals on semaglutide, tolerate it well and have no reason to change. Individual results vary.

If you are already on one medicine and wondering about the other, raise it at your next review rather than stopping or swapping on your own. What doctor-led treatment involves month by month, from first assessment to maintenance, is set out in what to expect. Whichever way the comparison leans on paper, the right option is decided by a doctor on assessment.

Frequently asked questions